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Background: Advances in biomedical nanotechnology raise hopes in patient populations 
but may also raise questions regarding biodistribution and biocompatibility, especially during 
pregnancy. Special consideration must be given to the placenta as a biological barrier because 
a pregnant woman’s exposure to nanoparticles could have significant effects on the fetus 
developing in the womb. Therefore, the purpose of this study is to optimize an in vitro model 
for characterizing the transport of nanoparticles across human placental trophoblast cells.
Methods: The growth of BeWo (clone b30) human placental choriocarcinoma cells for 
 nanoparticle transport studies was characterized in terms of optimized Transwell® insert type 
and pore size, the investigation of barrier properties by transmission electron microscopy, 
tight junction staining, transepithelial electrical resistance, and fluorescein sodium transport. 
 Following the determination of nontoxic concentrations of fluorescent polystyrene nanoparticles, 
the cellular uptake and transport of 50 nm and 100 nm diameter particles was measured using 
the in vitro BeWo cell model.
Results: Particle size measurements, fluorescence readings, and confocal microscopy indicated 
both cellular uptake of the fluorescent polystyrene nanoparticles and the transcellular transport 
of these particles from the apical (maternal) to the basolateral (fetal) compartment. Over the 
course of 24 hours, the apparent permeability across BeWo cells grown on polycarbonate 
membranes (3.0 µm pore size) was four times higher for the 50 nm particles compared with 
the 100 nm particles.
Conclusion: The BeWo cell line has been optimized and shown to be a valid in vitro model 
for studying the transplacental transport of nanoparticles. Fluorescent polystyrene nanoparticle 
transport was size-dependent, as smaller particles reached the basal (fetal) compartment at a 
higher rate.
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Introduction
Advances in nanotechnology are starting to have an impact in the biomedical and 
industrial fields. These advances raise hopes in patient populations regarding improved 
specificity and lower doses, but may raise concerns in environmental and occupational 
fields due to a lack of toxicity studies and other unwanted side effects. Particles with 
dimensions ranging from tens to hundreds of nanometers have unique characteristics 
that may be distinct from bulk material properties. The increased relative surface 
area of nanoparticles (NPs) compared to fine and ultrafine particle bulk material can 
lead to changes in physical, chemical, mechanical, thermal, electrical, magnetic, and 
luminescent properties.1 To appropriately estimate risks and to provide the public 
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with confidence in safety assessment for new technologies, 
the implementation of uniform protocols and integrated 
testing standards is imperative.2 These assessments should 
answer questions regarding both the biodistribution and 
the  biocompatibility of NPs as well as potential adverse 
effects such as genotoxicity, oxidative stress induction, and 
inflammation.
Amongst the various biological barriers in the human 
body, special consideration must be given to the placenta, 
because a pregnant woman’s exposure to NPs could have 
significant effects on the fetus developing in the womb.3 
While there is still much to be learned in this field, the first 
studies indicate that the physical and chemical nature of the 
particle is an important determinant. Myllynen et al recently 
demonstrated that polyethylene glycol (PEG)ylated gold NPs 
between 10 nm and 30 nm diameter did not pass into the fetal 
perfusate in perfused human placenta experiments;4 however, 
using a similar experimental model, Wick et al showed that 
the transport of fluorescently labeled polystyrene beads of 
50 nm and 240 nm diameter is size dependent.5
The placenta serves as the interface regulating the transfer 
of oxygen, nutrients, and waste products between the mater-
nal and fetal circulations. When exogenous substances are 
present in the maternal bloodstream, whether from environ-
mental contact, occupational exposure, medication, or drug 
abuse, the extent to which this exposure affects the fetus is 
determined by transport processes in the placental barrier. 
Inside the placenta, fetal blood vessels from the umbilical 
cord branch out in the formation of villous trees within coty-
ledons, or placental lobes. A placenta usually has between 
20 and 30 cotyledons at full-term. Maternal blood moves 
through the intervillous space and three layers separate the 
maternal and fetal blood flows: syncytiotrophoblast cells, 
connective tissue, and fetal vascular endothelium.6
Several experimental models have been implemented to 
study the disposition of substances across the human placenta, 
including cell lines, primary cultured cells, villous explants, 
isolated membrane vesicles, and the dually perfused placental 
cotyledon.7–9 The trophoblast cell layer is the rate-limiting 
barrier for drug and nutrient exchange between mother and 
fetus, and the human choriocarcinoma trophoblastic BeWo 
cell line is an established in vitro model for placental transport 
studies of soluble material.10 Although this model does not 
constitute a complete physiological system and the entire 
tissue microenvironment found in humans in vivo, it does 
represent the rate-limiting barrier of maternal-fetal exchange, 
irrespective of the transport mechanism through the cell 
 layers. Due to interspecies differences in placental structure, 
it cannot be assumed that observations in animal placentae 
are directly translatable to humans;11 therefore, this work 
has focused on a model of human origin. The transplacental 
transport of caffeine, benzoic acid, glyphosate, and antipy-
rine was recently compared in in vitro BeWo cells and in ex 
vivo human placental perfusion experiments, and excellent 
correlation between the results was observed.11 A similar 
correlation has also been observed for two polychlorinated 
biphenyls, PCB-52 and PCB-180.12 Additional examples of 
agreement between in vitro results from the BeWo cell model 
and clinical effects in vivo have been reported previously.13,14 
It should be noted that in contrast to the original American 
Type Culture Collection (Manassas, VA) BeWo cell line, 
the b30 BeWo clone forms confluent monolayers suitable 
for transport studies.15
Fluorescent polystyrene NPs have been employed in a 
number of scientific studies due to their similarities in size 
and zeta potential properties when compared to biocompat-
ible polymeric particles proposed for biomedical diagnostic 
and drug delivery applications.16 For example, fluorescent 
polystyrene NPs have been investigated in relation to aspi-
ration into the airways of rats,17 mucociliary clearance,16 
transport across rat and human pulmonary epithelial cells,18 
intravenous injection in rats,17 distribution in the skin,18,19 
uptake in rat and human hepatocytes,20 uptake in HeLa cells,21 
disposition in periocular and ocular rat tissue following sub-
conjunctival injection,22 and injection into extraembryonic 
mouse tissue.23
In this work, we investigate the uptake and transport of 
fluorescent polystyrene NPs in BeWo b30 cells following 
model optimization specific to the application of NPs. 
The BeWo cell model has long been utilized for placental 
transport,24 uptake,13 efflux,25 and expression studies;10 
however, we present a series of optimization procedures 
enabling the application of BeWo cells to transplacental NP 
transport experiments, thereby developing the use of this model 
beyond its conventional use with only soluble materials. The 
uptake of gold NPs was previously studied using the original 
(American Type Culture Collection) BeWo clone,4 and the 
BeWo b30 clone has been utilized within an elaborate model 
to show indirect effects of cobalt-chromium NPs on fibroblast 
cells cultured behind a BeWo cell layer even though these 
particles did not traverse the BeWo cell barrier.26
Materials and methods
Materials
Transwell® (Sigma-Aldrich, St Louis, MO) 12-well plates, 
12 mm diameter, polyester and polycarbonate 3 µm and 
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0.4 µm pore size (Appleton Woods Ltd, Birmingham, UK); 
Fluoresbrite® polystyrene latex NPs, 37 nm and 200 nm 
(Polysciences Inc, Northampton, UK) and 50 nm and 100 nm 
particles (Polysciences Inc, Warrington, PA); Dulbecco’s 
modified Eagle medium/nutrient F-12 Ham (DMEM-F12) 
with phenol red, supplemented with 1% (v/v) L-glutamine-
penicillin-streptomycin (PSLG), 1% (v/v) amphotericin B 
solution (AmpB); and 10% (v/v) fetal bovine serum (FBS) 
(Sigma-Aldrich, Dorset, UK). For transport studies using 
Fluoresbrite particles, DMEM-F12 without phenol red (Sigma-
Aldrich, Irvine, Ayrshire, UK) supplemented with 10% (v/v) 
FBS (In Vitro, Fredensborg, Denmark), 1% (v/v) penicillin/
streptomycin (Panum Institute, University of Copenhagen, 
Denmark) and 4 mM glutamine (In Vitro) was used, to avoid 
interference with optical absorbance; Hank’s balanced salt 
solution (HBSS), 4% (v/v) formaldehyde, dimethyl sulfoxide 
and 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay (Sigma-Aldrich, Irvine, Ayrshire, 
UK); fluorescein sodium salt (Na-Flu), paraformaldehyde 
(PFA), Triton X-100 (Sigma-Aldrich, Dorset, UK), trypsin-
ethylenediaminetetraacetic acid (EDTA; US Food and Drug 
Administration, Silver Spring, MD) and horse and goat sera 
(Sigma-Aldrich, Dorset, UK); primary polyclonal rabbit 
anti-human ZO-1 antibody (Zymed, South San Francisco, 
CA); Alexa Fluor® 488 donkey antirabbit secondary antibody 
(Invitrogen, Paisley, UK); phalloidin (Sigma-Aldrich, 
Dorset, UK); VECTASHIELD mounting medium with 
4′,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories 
Ltd, Peterborough, UK) for monolayer confirmation or 
VECTASHIELD mounting medium (Vector Laboratories 
Ltd, Burlingame, CA) for NP transport and uptake study; 
lysis solution (0.5% Triton X-100 in 0.2 M NaOH) (VWR, 
Herlev, DK).
Cell culture
The choriocarcinoma cell line BeWo b30 was obtained 
from Professor Harry McArdle (Rowett Research Institute, 
Aberdeen, UK) with permission from Dr Alan Schwartz 
(Washington University, St Louis, MO). Cells were cultured 
at 37°C with 5% CO
2
 in a humidified atmosphere in supple-
mented DMEM-F12 with phenol red. Experiments were con-
ducted using this media, unless otherwise stated. At confluence 
the cells were subcultured using trypsin-EDTA solution.
Model optimization
Nanoparticle adherence to Transwell membranes
To determine adsorption of the NPs to polycarbonate (PC) 
or polyester (PE) Transwell membranes with 0.4 µm or 3 µm 
diameter pores, membranes were exposed (in the absence of 
cells) to Fluoresbrite latex NPs for up to 6 hours to mimic 
experimental transport conditions. Fluoresbrite NPs of 37 nm 
and 200 nm diameter were used at nominal concentrations 
of 9.3 × 1013 particles/mL and 6.2 × 1011 particles/mL, 
 respectively. Dispersion in DMEM-F12 medium without phe-
nol red was achieved by vortexing for 1 minute and subsequent 
incubation for 10 minutes in a sonicating water bath (MXB6, 
Grant Scientific, Shepreth, Cambridgeshire, UK), followed by 
vortexing for 1 minute. Initial particle characterization studies 
had demonstrated that 100 nm Fluoresbrite nanosuspensions 
at a nominal concentration of 1 mg/mL (1.8 × 1012 particles/
mL) in DMEM containing 10% FBS were stable, showing no 
agglomeration or precipitation. Fluoresbrite particles dispersed 
in 0.5 mL of medium were added to the apical chamber of the 
Transwell and 1.5 mL phenol red-free medium was added to the 
basal chamber. Plates were incubated at 37°C and 5% CO
2
 to 
mimic experimental conditions. Samples of 50 µL were taken 
in triplicate from the basal chamber into a black 96-well plate 
(Corning, New York, NY) at 5- and 30-minute, and 1-, 2-, 4-, 
and 6-hour intervals and read at excitation 485 nm and emis-
sion 520 nm on a FluoSTAR OPTIMA fluorescence microplate 
reader (BMG Labtech, Aylesbury, UK). After 6 hours, mem-
branes were removed and mounted for imaging. The degree of 
fluorescent particle adherence to the membrane was observed 
using a Leica™ SP5 confocal (Wetzlar, Germany) attached to 
a Leica DMI 6000 inverted microscope and a 63× (1.4NA) 
oil-immersion objective. Imaging parameters were selected 
to optimize resolution and images were acquired with Leica 
confocal software.
Monolayer characterization
BeWo cells were seeded on PC Transwell membranes (3 µm 
pore size) at 1 × 105 cells/cm2 and incubated at 37°C and 
5% CO
2
. Medium was changed on days 3, 4, and 5 postseed-
ing (PS). Development of the monolayer was monitored on 
these days using transepithelial electrical resistance (TEER) 
measurements followed by Na-Flu transport, transmission 
electron microscopy (TEM) and tight junction staining.
TEER measurements
Monolayer integrity was measured with an Endohm 
12 chamber and EVOM voltohmeter (World Precision Instru-
ments Ltd, Stevenage, UK) containing 3 mL of medium at 
23°C. TEER values for the cell layer were obtained by sub-
tracting the intrinsic resistance (blank insert membrane) from 
the total resistance (insert membrane with cells). TEER values 
were corrected for surface area and expressed as Ω ⋅ cm2.
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Na-Flu transport
Cell confluence was determined by retardation of Na-Flu 
transport across the monolayer. A 0.5 mL aliquot of 5 µM Na-
Flu was added to the apical chamber and 1.5 mL of DMEM-
F12 medium (without phenol red) to the basal  chamber of 
each Transwell. Plates were incubated for 3 hours, after 
which time 50 µL samples were removed in triplicate from 
the basal chamber into a black 96-well plate and read as 
described previously.
Transmission electron microscopy
BeWo cells grown on insert membranes were fixed and 
processed according to Lahtinen et al.27 After ultrathin sec-
tioning, the samples were analyzed using an FEI Tecnai 12 
Biotwin transmission electron microscope (TEM) equipped 
with a bottom-mount 4 × 4k FEI Eagle™ 4k CCD camera 
(FEI Company, Hillsboro, OR).
Tight junction staining
To quantify the integrity of the confluent cell monolayer, 
antibody staining of the tight junctions was performed on 
day 3 PS. BeWo cells grown on PC Transwell membranes 
(3 µm pores) were f ixed in 2% (v/v) PFA at 4°C for 
1 hour, washed in phosphate-buffered saline (PBS) and 
permeabilized with 0.3% Triton-X-100 for 15 minutes at 
room temperature. Cells were incubated with a blocking 
agent (5% horse serum: 5% goat serum in PBS) for 1 hour 
at room temperature.  Primary rabbit anti-ZO-1 was diluted 
(1:200) in blocking agent (3% horse serum: 3% goat 
serum in PBS) and incubated with the cells overnight at 
4°C. Secondary antibody (1:200 dilution in PBS) was 
incubated with the cells for 1 hour at room temperature in 
the dark. Membranes were mounted on glass slides using 
VECTASHIELD mounting media (Vector Laboratories, 
Burlingame, CA) with DAPI. Staining was observed using 
a Leica™ SP5 confocal attached to a Leica DMI6000 
(Wetzlar, Germany) inverted microscope and a 63X 
(1.4NA) oil-immersion objective. Imaging parameters were 
selected to optimize resolution and images were acquired 
with Leica confocal software.
Transport and uptake of Fluoresbrite 
particles
Particle characterization
Mean NP diameter was determined before and after  transport 
experiments by dynamic light scattering using photon 
 correlation spectroscopy. Measurements were performed on 
undiluted pooled samples at 25°C using a Malvern NanoZS 
(Malvern Instruments Ltd, Worcestershire, UK) equipped 
with a 633 nm laser and 173° detection optics.
MTT cytotoxicity assay
BeWo b30 cells were seeded at 1 × 104 cells/well in 
96-well plates and incubated at 37°C and 5% CO
2
 for 
24 hours, followed by exposure to a range of Fluoresbrite 
concentrations from 0 mg/mL to 1 mg/mL with 0 mg/mL 
acting as the negative control. Cells were exposed to Triton 
X-100 at 0.1% (v/v) as the positive control. After 24 hours, 
NPs were removed and the cells were washed three 
times in PBS before incubation with 0.5 mg/mL MTT 
(3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl-tetrazolium 
bromide). After 2 hours’ incubation, the MTT was removed 
and 100 µL/well dimethyl sulfoxide was added to dissolve 
the crystals. The plates were rotated at 900 rpm for 1 minute 
and absorbance was measured at 550 nm using a Multiscan 
ascent plate reader (Thermo Labsystems, Helsinki, Finland). 
Any interference of particle fluorescence on the absorbance 
readings was monitored and accounted for.
Transport of Fluoresbrite nanoparticles
BeWo cells were seeded at 1 × 105 cells/cm2 on PC 
membrane Transwells (pore size 3 µm) and grown to 
confluence as described above, using the optimized 
protocol for Fluoresbrite NPs. Experiments were conducted 
in supplemented DMEM-F12 without phenol red. 
Fluoresbrite 50 nm and 100 nm NPs at a concentration 
of 0.5 mg/mL were dispersed using a Branson Sonifier 
S-450D (Branson Ultrasonic Corporation, Danbury, CT) 
equipped with a disruptor horn (model 101-147-037) with 
amplitude setting 10% (21 µm peak-to-peak movement) in 
an ice-water bath for 20 minutes, with alternating 5 second 
pulse/5 second pause.
Transport of Fluoresbrite NPs across the BeWo cell 
monolayer was carried out under standard cell culture 
conditions with constant horizontal shaking (10 rpm). 
At t
0
, 0.5 mL of 0.5 mg/mL NP dispersion (0.22 mg/
cm²) was added to the apical chamber. At successive time 
points (2 hours, 4 hours, 6 hours, 12 hours and 24 hours), 
a 100 µL sample was removed from the basal chamber and 
replaced with 100 µL of fresh medium. A 10 µL sample 
was removed from the apical chamber to allow correlation 
of the changing particle concentrations in each chamber. 
Fresh medium (40 µL) was added to samples from the 
apical chamber to ensure sufficient sample volume for 
analysis, with appropriate concentration corrections based 
on this dilution. Each sample was placed in a 96-well 
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plate and immediately analyzed for  fluorescence. After the 
final time point, cells on the Transwell were  prepared 
for quantitative uptake analysis: Inserts with cells were 
washed three times in ice cold HBSS and membranes 
were removed and submerged in 1 mL of lysis solution. 
Cell lysates were placed on a stir plate for 2 hours at 
37°C. Each 100 µL sample was placed in a 96-well plate 
and analyzed for fluorescence to determine the amount of 
particles in  association with the cells. Statistical analysis of 
size dependent transport and uptake was performed using a 
two-tailed paired Student’s t-test in Microsoft Excel 2007 
(Redmond, WA).
Uptake of Fluoresbrite particles
For imaging analysis, cells were exposed to Fluoresbrite 
NPs and treated as for transport. After 2 hours and 24 hours 
exposure, cells were stained with wheat germ agglutinine 
(WGA) Alexa 594 (Invitrogen, DK) at 5 µg/mL for 10  minutes 
at room temperature and fixed in 4% formaldehyde for 
15 minutes at room temperature. Membranes were mounted 
on glass slides using VECTASHIELD mounting medium. 
Staining was observed using a Zeiss LSM 780 confocal 
system on an inverted stand with a 63X oil DIC Plan-
Apochromat objective (Carl Zeiss Microscopy, LLC, New 
York, NY). Imaging parameters were selected to optimize 
resolution and images were acquired with Imaris Bitplane 
scientific software (Bitplane AG, Zurich, Switzerland).
Sample analysis and data processing
Fluoresbrite concentrations in the samples were analyzed 
at excitation 440 nm and emission 485 nm on a  Fluorescan 
ascent FL (Thermo Electron Corporation, Vantaa, 
Finland).
For samples at each time point t = t
n
, the mass transported 
(∆Q
n
) was determined and corrected for the mass removed 
during the previous sampling periods using the following 
equation:
 ∆Q C V C Vn n w j s
j
n
= ⋅ + ⋅
=
−
∑
1
1
 (1)
where C
n
 is the concentration of the sample measured at time 
t
n
, V
w
 is the volume of the well sampled (usually either 0.5 mL 
or 1.5 mL in 12-well Transwells®), V
s
 is the sampling volume 
(in our case, 100 µL and 10 µL), and the term 
j
n C Vj s=
−∑ ⋅1
1
 
represents the correction for the cumulative mass removed 
by sampling during all the sampling periods prior to t
n
 (from 
t = t
1
 until t = t
n–1
).11
The data were converted to permeability values (P), using 
the following equation:
 P
Q
t
A C
=
⋅
∆
∆
0
 (2)
where ∆Q/∆t is the rate of the substance flux across a layer 
(mass/second), A is the surface area of the layer (in cm2), and 
C
0
 is the initial concentration of the substance on the donor 
side (in mass/cm3).11 Permeability (P) of the substance is 
expressed as cm/second.
To calculate the permeability across the cell monolayer 
alone (and to correct for the influence of the membrane 
on permeability), transport of the substance across blank 
membranes (Transwell membranes alone without cells) was 
measured. Permeability in these experiments with blank 
membranes (P
m
) and permeability in the experiments with 
cells on membranes (P
t
) were then applied to the following 
equation11 to calculate the apparent permeability across the 
cell monolayer alone (P
e
):
 P
P P
e
t m
=
−



1
1 1  (3)
Results
Model optimization
Nanoparticle adherence to Transwell membranes
Fluoresbrite adherence to PE and PC 0.4 µm and 3 µm 
Transwell membranes was assessed over a 6-hour time 
course using both 37 nm and 200 nm particles (9.3 × 1013 
and 6.2 × 1011 particles/mL, respectively). Results showed 
greater particle adherence to the PE membranes (Figure 1), 
hence these were eliminated from the study and further model 
development proceeded on PC membranes.
Nanoparticle transport across blank  
Transwell membranes
Fluoresbrite transport across PC 0.4 µm and 3 µm Tran-
swell membranes was assessed over a 6-hour time course 
using both 37 nm (Figure 2) and 200 nm (data not shown) 
particles. The smaller pore size extensively restricted the 
transfer of particles across the membrane from apical to basal 
chambers, with transfer leveling off over 6 hours. Therefore, 
3 µm PC membrane inserts were chosen for further model 
development.
Monolayer confirmation
As a result of preliminary NP adherence and transport 
experiments, PC Transwell membranes with 3 µm pore 
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Figure 1 Fluoresbrite® adherence to PE and PC 0.4 µm and 3 µm Transwell membranes was assessed over a 6-hour time course using both 37 nm and 200 nm particles 
(9.3 × 1013 and 6.2 × 1011 particles/mL, respectively, 200 nm data not shown). Photographs are comparable in the vertical direction only, due to necessary differences in gain 
settings. PE membranes show a greater adherence of Fluoresbrite particles and therefore were eliminated from the study.
Abbreviations: PC, polycarbonate; PE, polyester.
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Figure 2 Transport of 37 nm Fluoresbrite® particles across 0.4 µm and 3 µm pore size PC membranes. Fluoresbrite particles at a concentration of 9.3 × 1013 particles/mL 
were added to the apical chamber at time zero and samples were collected from the basal chamber at time intervals up to 6 hours.
Note: Results are expressed as the mean concentration ± SD (n = 3).
Abbreviations: PC, polycarbonate; SD, standard deviation.
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size were chosen for model optimization. BeWo cells were 
seeded on membranes at 1 × 105 cells/cm2. Development of 
the monolayer was monitored on days 3, 4 and 5 PS using 
TEER measurements followed by Na-Flu transport, TEM and 
confocal microscopy, allowing a direct comparison between 
these parameters for each day.
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Figure 3 Formation of monolayers on PC Transwells with 3 µm pores was measured using TEER and Na-Flu transport. Monolayers (insert plus cells) were compared with 
blank inserts (insert alone) on days 3, 4 and 5 PS and TEER values were blank-corrected. (A) Mean TEER values ± SD (n = 3). (B) Concentration of Na-Flu detected in basal 
chamber 3 hours after apical application. Values are corrected for background fluorescence and expressed as mean ± SD (n = 3).
Abbreviations: PC, polycarbonate; PS, post-seeding; SD, standard deviation; TEER, transepithelial electrical resistance.
TEER and Na-Flu data confirmed the development of a 
BeWo monolayer over 5 days PS, with a steady increase in 
TEER and Na-Flu retardation rising to a maximum on day 
5 PS (Figure 3A and B, respectively).
TEM images on days 3, 4, and 5 PS show that a conflu-
ent monolayer with visible tight junctions is formed on day 
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3 PS (Figure 4). Antibody staining for tight junction protein 
ZO-1 was performed on day 3 PS to examine barrier integrity 
in the confluent cell monolayer. DAPI counter-stain was used 
to visualise the nuclei. The presence of tight junction protein 
ZO-1 was observed (Figure 5), which lends support to the 
progression of confluent monolayer formation indicated in 
the TEM images.
Transport and uptake of Fluoresbrite 
nanoparticles
Particle characterization
The size of the Fluoresbrite NPs can be considered 
stable during the 24-hour transport experiment, since 
A
C
E
B
D
F
10 µm 500 nm
Figure 4 TEM imaging of BeWo cells grown on PC membranes with 3 µm pore size. (A and B) day 3 PS; (C and D) day 4 PS; (E and F) day 5 PS.
Notes: Arrows indicate tight junctions. There is evidence of monolayer formation at day 3 PS and overgrowth by day 5 PS.
Abbreviations: PS, post-seeding; TEM, transmission electron microscopy.
the Z-average size of the particles in samples from both 
chambers changed only slightly compared to the initial 
size (Table 1).
Photon correlation spectroscopy measurements demon-
strated that the 50 nm particles had a single size intensity 
peak at 52 nm when added to the apical chamber at t
0
. At 
the end of the experiment, they were shown to have a 53 nm 
peak in apical samples and 46 nm peak in basal samples, 
with a small percentage of larger aggregates which had a 
peak at 346 nm. The 100 nm particles were shown to have 
one peak at 104 nm at t
0
 and 96 nm in apical samples at 
the end of the experiment. In the basal samples, the peak 
was at 94 nm.
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MTT cytotoxicity assay
The results of the MTT assay demonstrated that exposure 
to 50 nm or 100 nm Fluoresbrite particles at up to and 
including 0.8 mg/mL demonstrated no significant toxicity 
compared to the unexposed negative control (Figure 6). 
However, concentrations of particles at 1 mg/mL exhibited 
toxicity as determined by the MTT assay. A concentration of 
0.5 mg/mL was therefore selected for use in transport studies 
as it showed no toxicity.
Transport of Fluoresbrite nanoparticles
After 24 hours, approximately 0.6% of the initial amount of 
100 nm particles added to the apical chamber of a cell mono-
layer was found in the basal chamber. The 50 nm particles 
were transported approximately six times faster, as 3.5% of 
the initial amount added to the apical chamber was found in 
the basal chamber (Figure 7).
This size-dependent difference in particle transport after 
24 hours is statistically significant (P value 0.002). For the 
50 nm particles, the apparent permeability across the cell 
monolayer alone after 2 hours (3.8 ± 1.1 × 10−5 cm/s) was 
more than twice as high as the P
e
 for the 100 nm particles 
(1.8 ± 0.7 × 10−5 cm/s, P value 0.003, see Table 2).
The average mass of 50 nm and 100 nm particles asso-
ciated with the cells after 24 hours was 25 ± 30 µg and 
2 ± 2 µg, respectively (10% and 0.8% of the initial amount 
of NPs), suggesting size-dependent cellular uptake. Although 
the difference in uptake between the two particles sizes is 
not statistically significant (P value 0.096), perhaps a larger 
sample size would further highlight this difference. Confocal 
microscopy confirmed cellular accumulation of the 50 nm 
particles over time, indicating that particle transport may be 
transcellular (Figure 8).
Mass balance calculations after 24 hours indicate greater 
adhesion of the 100 nm particles to the PC membrane com-
pared to the 50 nm particles, but this is not unexpected, as 
some degree of particle adhesion to PC membranes had been 
observed during the methods optimization experiments (see 
Figure 1).
Discussion
The novelties of nanoparticle technology give rise to the 
need for adapting our current testing models and methods to 
accommodate the challenges specific to this area of biologi-
cal risk assessment. The aim of this work was to develop an 
optimized in vitro model of the placental barrier, suitable for 
use in measuring the transport of NPs. Each NP has unique 
properties, and a study encompassing every particle type is 
unrealistic; therefore, we have used Fluoresbrite as a model 
NP, allowing us the advantage of experience to extrapolate 
the primary issues and concerns that researchers should bear 
in mind when undertaking similar studies.
The BeWo model is a well-recognized in vitro model of 
the placental trophoblast layer;15 therefore, its use in NP trans-
port and toxicity testing is justified. However, there are many 
discrepancies in the literature regarding the precise details 
of the Transwell matrix used, details such as  membrane 
type, collagen coating, culture media and TEER values, all 
of which affect the length of time taken for formation of a 
Figure 5 BeWo monolayer (day 3 PS) grown on PC membranes with 3 µm pore 
size, showing ZO-1 tight junction protein staining. 
Notes: Blue, DAPI; Green, ZO-1 tight junction protein. Field of view 179 × 153 µm.
Abbreviations: DAPI, 4′,6-diamidino-2-phenylindole; PS, postseeding.
Table 1 Fluoresbrite® nanoparticle sizes before and after transport across a BeWo cell monolayer
Time Sample Mean size (nm) Peak 1 (nm) Peak 1% Peak 2 (nm) Peak 2%
0 h Blank transport medium 19 13 93 126 5
50 nm: 0.5 mg/mL 56 52 100
100 nm: 0.5 mg/mL 97 104 100
24 h 50 nm apical 57 53 100
100 nm apical 98 96 100
50 nm basal 57 46 95 346 4
100 nm basal 79 94 82 12 13
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Figure 6 Viability of BeWo cells exposed to different concentrations of Fluoresbrite® nanoparticles as assessed by MTT assay. Cells were incubated for 24 hours with media 
containing Fluoresbrite nanoparticles of 50 nm (filled bars) or 100 nm (hatched bars) diameter ranging in concentration from 0 mg/mL (negative control) to 1.0 mg/mL. Triton 
X-100 was used at 0.1% (v/v) as a positive control. At the end of the incubation period, mitochondrial function was determined by the MTT reduction assay as described in the 
text. The absorbance value for the negative control was set to 100% and the percentage change in absorbance was calculated for the exposed groups and the positive control.
Notes: The data are expressed as mean ± SD of four replicates. A one-way analysis of variance with Games-Howell post-hoc test was used to determine a significant decrease in cell 
viability. ***P , 0.05 compared to control.
Abbreviations: MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; SD, standard deviation.
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Figure 7 Total mass (delta Q) of Fluoresbrite® NP transported across BeWo monolayers in the apical to basal direction, corrected for concentration changes in the 
chambers. 
Notes: Size 50 nm particles were transported across monolayers at a rate six-fold higher than 100 nm particles. Mean values shown ± SD (n = 6).
Abbreviation: SD, standard deviation.
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complete monolayer. This picture becomes more complicated 
when particles are involved. In contrast to liquids or tradi-
tional small molecules, a matrix is required which does not 
bind the particles. The Transwell matrix is commonly used 
for transport studies across cellular barriers,12,15 and different 
Transwell membrane types are available, primarily PE or PC. 
Particle adherence to the membrane would effectively remove 
the particles from the experimental system, thereby altering 
the particle concentration in the donor and receiver chambers 
and biasing the results. We found that Fluoresbrite NPs had 
a greater adherence to PE than to PC Transwell membranes. 
Factors such as the surface charge of these materials may 
play a part in this observation. Our findings have implica-
tions for model optimization when NP transport across a 
barrier is studied. Care should be taken to first examine the 
adherence of the particles to the test system in the absence of 
cells, to ensure a robust experimental design. Besides particle 
adherence to the membranes, particle agglomeration within 
the transport medium should also be considered. Although 
particle agglomeration may pose a significant influence on 
the transport of nanoparticles across a biological barrier, the 
particle size data presented in Table 1 indicate that this was 
not an overriding factor in these studies. Toxicity studies were 
also performed to ensure that at the particle concentration 
employed in the transport studies (0.5 mg/mL) was not toxic. 
The reduced cell viability observed at higher concentrations 
(Figure 6) is most likely due to proinflammatory effects, as 
reported previously for this particle type.28
In the present study, we have outlined the optimization of 
the BeWo model on PC membranes in detail. The inclusion 
of TEM and confocal images provided visual confirmation to 
validate this model. Tight junctions could be seen 3 days PS, 
and the increased TEER values, together with the decreased 
Na-Flu transport data, indicated the extent to which these 
tight junctions strengthened over the subsequent 48 hours. 
As BeWo cells are not contact inhibited, care must be taken to 
ensure that they do not form multiple layers over time, which 
could result in a loss of the desired monolayer characteristics. 
In fact, previous work with this cell line has demonstrated 
that after 7 days, the TEER declines and Na-Flu transport 
increases.11 In a separate study, although some degree of 
multilayer growth of b30 BeWo cells was observed, the cells 
still formed tight junctions and were adequately polarized to 
show assymetric iron transport.29 Since TEER values may 
vary, depending on the membrane type the cells are grown 
on, the pore size used, and the type of TEER apparatus 
used (chopstick or chamber electrodes), comparisons of 
absolute TEER values within the literature can be difficult. 
 Nevertheless, visual confirmation of a monolayer added 
confidence to the robustness of the present study, and these 
images assisted in the development of standard operating 
procedures and optimal cell culturing conditions appropri-
ate to study the transfer of nanoparticles across a monolayer 
model of human placental trophoblast cells.
Collagen-coating Transwell membranes is often used 
to improve cell adherence. However, we have seen that the 
presence of collagen in a transport model can increase NP 
adherence (data not shown), and thus any model that includes 
collagen-coating the membranes should be tested for particle 
binding properties prior to transport studies. We found that 
monolayer formation occurred more rapidly and with a more 
even distribution on uncoated membranes, therefore we did 
not use collagen-coating.
The transport of 50 nm NPs showed a six-fold higher rate 
across the BeWo monolayer and a two-fold higher transport 
rate across blank membranes when compared to 100 nm NPs. 
The permeability data in Table 2 further corroborate these 
findings, as the calculation of apparent permeability accounts 
for transport across the blank membranes and any differences 
in particle binding to the Transwell inserts. The P
e
 values for 
transport across the cell monolayer were significantly higher 
at all time points for the 50 nm particles, compared to the 
100 nm particles. Besides the differences in the transport 
rates, the slight decrease in P
e
 over time for the 100 nm 
particles also suggests size-dependent differences in the 
transport mechanisms, and additional studies are  necessary 
to further investigate this possibility.
This size-dependent transport of particles across the 
 placental barrier is in agreement with the ex vivo studies 
recently reported by Wick et al.5 This further supports the 
validity of this model for nanoparticle transport studies, 
just as we have shown previously for the transplacental 
transport of small molecules.11,12 The confocal images of 
NP localization within the monolayer (Figure 8)  suggest 
Table 2 Apparent permeability (Pe) of Fluoresbrite
® particles 
(50 nm and 100 nm particle diameters) across a monolayer of 
human placental choriocarcinoma (BeWo) cells. Pe was calculated 
as described in the text, and the P values compare six replicates 
of each experiment
Time point (h) Pe (cm/s) P-value
50-nm particles 100-nm particles
2 3.8 ± 1.1 × 10−5 1.8 ± 0.7 × 10−5 0.003
4 3.6 ± 1.4 × 10−5 1.5 ± 1.0 × 10−5 0.013
6 4.4 ± 1.3 × 10−5 1.1 ± 0.8 × 10−5 ,0.001
12 4.2 ± 1.2 × 10−5 1.1 ± 0.9 × 10−5 ,0.001
24 3.9 ± 0.5 × 10−5 9.7 ± 9.4 × 10−6 ,0.001
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that the particles take a transcellular route through the 
monolayer. Future transcytosis studies will enable the 
determination of more details regarding the transport 
mechanisms.
Conclusion
We have demonstrated that the study of the transplacental 
kinetics of NPs can be performed using the placental BeWo 
model. This model provides a high throughput screening 
alternative to in vivo and ex vivo experimental methods, 
and is an effective tool in reducing, replacing and refining 
the use of animals in nanotechnology research. We have 
highlighted several points that must be taken into account 
for an effective, robust experimental model. In vitro cell 
barrier models used in the study of NP transport should 
undergo careful optimization for suitability of use for each 
NP exposed to them. Binding of NPs to the system’s matrix 
should be minimized as much as feasibly possible to ensure 
accurate transport results. Model optimization using visual 
techniques is essential to ensure monolayer formation, which 
may be influenced by matrix type, as TEER measurement 
alone may not be sufficient.
2 hrs
24 hrs
Figure 8 Confocal images of 50 nm Fluoresbrite® NP uptake into BeWo cells after 2 hours and 24 hours. 
Notes: Red, WGA membrane stain; yellow, Fluoresbrite NPs.
Abbreviations: NP, nanoparticles; WGA, wheat germ agglutinine.
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We found that 50 nm and 100 nm Fluoresbrite NPs are 
transported across the BeWo monolayer, with the former hap-
pening at a faster rate than the latter, indicating a size-dependant 
relationship. There is some evidence to suggest that the particles 
are transported transcellularly, and further research will provide 
more details regarding the transport mechanisms.
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